Overview Dividends

(CLDX) Celldex Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US15117B2025

Monoclonal Antibody, Bispecific Antibody, KIT Inhibitor, Thymic Stromal Lymphopoietin Neutralizer

EPS (Earnings per Share)

EPS (Earnings per Share) of CLDX over the last years for every Quarter: "2020-09": -0.36, "2020-12": -0.55, "2021-03": -0.42, "2021-06": -0.34, "2021-09": -0.45, "2021-12": -0.43, "2022-03": -0.49, "2022-06": -0.59, "2022-09": -0.57, "2022-12": -0.56, "2023-03": -0.62, "2023-06": -0.65, "2023-09": -0.81, "2023-12": -0.83, "2024-03": -0.56, "2024-06": -0.54, "2024-09": -0.64, "2024-12": -0.71, "2025-03": -0.81, "2025-06": -0.85, "2025-09": -1.01,
EPS Growth (3y CAGR): -52.21%
EPS Trend (3y Corr): -60.4%
Last SUE: -1.22σ
Qual. Beats: 0

Revenue

Revenue of CLDX over the last years for every Quarter: 2020-09: 0.668, 2020-12: 3.786, 2021-03: 0.685, 2021-06: 3.48, 2021-09: 0.153, 2021-12: 0.333, 2022-03: 0.174, 2022-06: 0.163, 2022-09: 0.407, 2022-12: 1.613, 2023-03: 0.967, 2023-06: 0.268, 2023-09: 1.517, 2023-12: 4.131, 2024-03: 0.156, 2024-06: 2.498, 2024-09: 3.191, 2024-12: 1.175, 2025-03: 0.695, 2025-06: 0.73, 2025-09: 0,
Revenue Growth (3y CAGR): -63.56%
Revenue Trend (3y Corr): -24.2%
Last SUE: -0.73σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 54.4%
Value at Risk 5%th 81.5%
Relative Tail Risk -8.82%
Reward TTM
Sharpe Ratio 0.18
Alpha -9.74
Character TTM
Hurst Exponent 0.304
Beta 1.057
Beta Downside 0.830
Drawdowns 3y
Max DD 70.84%
Mean DD 36.15%
Median DD 35.91%

Description: CLDX Celldex Therapeutics November 12, 2025

Celldex Therapeutics, Inc. (NASDAQ: CLDX) is a U.S.-based biopharma focused on antibody therapeutics for severe inflammatory, allergic, and autoimmune conditions, with its headquarters in Hampton, New Jersey.

The company’s lead programs are Barzolvolimab (CDX-0159), a KIT-receptor monoclonal antibody targeting chronic urticaria, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis, and CDX-622, a bispecific antibody that simultaneously neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells by starving them of stem cell factor.

As of the most recent 10-Q (Q2 2024), Celldex reported $115 million in cash and marketable securities, giving it runway through at least 2026 without additional financing-a key KPI for early-stage biotech cash burn management.

The chronic urticaria market is projected to exceed $4 billion by 2028, while the broader biologics segment for inflammatory skin diseases is growing at a CAGR of ~12%, providing a sizable addressable market for Celldex’s pipeline.

Given the high unmet need and the company’s differentiated dual-target approach, analysts should monitor upcoming Phase 2 readouts and the potential impact of FDA guidance on bispecific antibody pathways.

For a deeper, data-driven assessment of CLDX’s valuation and risk profile, you may find the ValueRay analytics platform useful as a next step in your research.

CLDX Stock Overview

Market Cap in USD 1,576m
Sub-Industry Biotechnology
IPO / Inception 2008-03-10
Return 12m vs S&P 500 -12.0%
Analyst Rating 4.57 of 5

CLDX Dividends

Currently no dividends paid

CLDX Growth Ratios

Metric Value
CAGR 3y -7.92%
CAGR/Max DD Calmar Ratio -0.11
CAGR/Mean DD Pain Ratio -0.22
Current Volume 591.2k
Average Volume 822.4k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-224.5m TTM) > 0 and > 6% of Revenue (6% = 156.0k TTM)
FCFTA -0.28 (>2.0%) and ΔFCFTA -8.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 21.5k% (prev 7485 %; Δ 14.0kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.28 (>3.0%) and CFO -179.5m > Net Income -224.5m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 13.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (66.4m) change vs 12m ago 0.19% (target <= -2.0% for YES)
Gross Margin -2352 % (prev 68.76%; Δ -2421 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.35% (prev 1.21%; Δ -0.86pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -9.93 (EBITDA TTM -246.3m / Interest Expense TTM -25.1m) >= 6 (WARN >= 3)

Altman Z'' -41.60

(A) 0.86 = (Total Current Assets 604.3m - Total Current Liabilities 46.5m) / Total Assets 648.4m
(B) -2.67 = Retained Earnings (Balance) -1.73b / Total Assets 648.4m
warn (B) unusual magnitude: -2.67 — check mapping/units
(C) -0.34 = EBIT TTM -249.7m / Avg Total Assets 735.8m
(D) -34.52 = Book Value of Equity -1.73b / Total Liabilities 50.1m
Total Rating: -41.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 37.65

1. Piotroski 0.0pt
2. FCF Yield -18.25%
3. FCF Margin data missing
4. Debt/Equity 0.00
5. Debt/Ebitda 0.14
7. RoE -33.22%
8. Rev. Trend -24.23%
9. EPS Trend -60.40%

What is the price of CLDX shares?

As of November 22, 2025, the stock is trading at USD 25.92 with a total of 591,228 shares traded.
Over the past week, the price has changed by +1.45%, over one month by -7.13%, over three months by +17.71% and over the past year by -1.14%.

Is CLDX a buy, sell or hold?

Celldex Therapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy CLDX.
  • Strong Buy: 10
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CLDX price?

Issuer Target Up/Down from current
Wallstreet Target Price 53.1 105%
Analysts Target Price 53.1 105%
ValueRay Target Price 25.5 -1.5%

CLDX Fundamental Data Overview November 15, 2025

Market Cap USD = 1.58b (1.58b USD * 1.0 USD.USD)
P/S = 606.4569
P/B = 2.6941
Beta = 1.135
Revenue TTM = 2.60m USD
EBIT TTM = -249.7m USD
EBITDA TTM = -246.3m USD
Long Term Debt = 2.62m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.55m USD (from shortTermDebt, last quarter)
Debt = 2.62m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -33.4m USD (from netDebt column, last quarter)
Enterprise Value = 995.6m USD (1.58b + Debt 2.62m - CCE 583.2m)
Interest Coverage Ratio = -9.93 (Ebit TTM -249.7m / Interest Expense TTM -25.1m)
FCF Yield = -18.25% (FCF TTM -181.7m / Enterprise Value 995.6m)
FCF Margin = -6987 % (FCF TTM -181.7m / Revenue TTM 2.60m)
Net Margin = -8636 % (Net Income TTM -224.5m / Revenue TTM 2.60m)
Gross Margin = -2352 % ((Revenue TTM 2.60m - Cost of Revenue TTM 63.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev 100.0%)
Tobins Q-Ratio = 1.54 (Enterprise Value 995.6m / Total Assets 648.4m)
Interest Expense / Debt = 118.7% (Interest Expense 3.11m / Debt 2.62m)
Taxrate = 100.0% (out of range, set to none) (-157.9m / -157.9m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 13.01 (Total Current Assets 604.3m / Total Current Liabilities 46.5m)
Debt / Equity = 0.00 (Debt 2.62m / totalStockholderEquity, last quarter 598.4m)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -33.4m / EBITDA -246.3m)
Debt / FCF = 0.18 (negative FCF - burning cash) (Net Debt -33.4m / FCF TTM -181.7m)
Total Stockholder Equity = 675.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.63% (Net Income -224.5m / Total Assets 648.4m)
RoE = -33.22% (Net Income TTM -224.5m / Total Stockholder Equity 675.9m)
RoCE = -36.79% (EBIT -249.7m / Capital Employed (Equity 675.9m + L.T.Debt 2.62m))
RoIC = -1331 % (out of range, set to none) (EBIT -249.7m / (Assets 648.4m - Curr.Liab 46.5m - Cash 583.2m))
WACC = 9.89% (E(1.58b)/V(1.58b) * Re(9.91%) + (debt cost/tax rate unavailable))
Discount Rate = 9.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.99%
Fair Price DCF = unknown (Cash Flow -181.7m)
EPS Correlation: -60.40 | EPS CAGR: -52.21% | SUE: -1.22 | # QB: 0
Revenue Correlation: -24.23 | Revenue CAGR: -63.56% | SUE: -0.73 | # QB: 0

Additional Sources for CLDX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle